Top Story

Caplacizumab induces rapid response for acquired TTP

February 10, 2016

Caplacizumab induced a faster response time than placebo among patients with acquired thrombotic thrombocytopenic purpura, a rare blood-clotting disorder, according to phase 2 study results published in The New England Journal of Medicine.

However, caplacizumab (Ablynx) — an anti-von Willebrand factor humanized single-variable domain immunoglobulin — also appeared associated with an increased tendency toward bleeding.


VIDEO: Physicians have ‘3 main opportunities’ to reduce colorectal cancer in younger patients

February 10, 2016
As the prevalence of colorectal cancer rises “slowly and steadily” among patients under the age of 50 years, clinicians have three major opportunities to…

Hereditary cancer foundation launches Lynch Syndrome patient registry

February 10, 2016
AliveAndKickn has announced the launch of the HEROIC Registry, a genetic database for people with Lynch Syndrome to share data and further research, according to a press…
In the Journals

Obesity linked to poor outcomes in acute promyelocytic leukemia

February 10, 2016
Obesity appeared significantly associated with shorter DFS and OS among adult patients with acute promyelocytic leukemia, according to a pooled analysis of four clinical…
FDA News

FDA places full clinical hold on pacritinib

February 10, 2016
The FDA has placed a full clinical hold on studies that involve pacritinib, an oral tyrosine kinase inhibitor in development for the treatment of patients with…
More News Headlines »

World Lung Updates: Immunotherapy in NSCLC

This activity is supported by an educational grant from Genentech, Inc and Merck & Co., Inc.

Globally, lung cancer is the leading cause of cancer-related deaths. Non-small cell lung cancer (NSCLC) accounts for…
More »
Meeting News CoverageVideo

VIDEO: Negative ACCORD trial results reinforce standard of care for rectal cancer

January 27, 2016
More »

Updates in Immunotherapy – Philadelphia 2015

This activity is supported by an educational grant from Merck & Co., Inc.

The promise of immunotherapy in oncology has become a reality with the US Food and Drug Administration (FDA) approval…
More »
Current Issues
View the Current Issue
HemOnc Today
morganatic-roan morganatic-roan